ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...
ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...
I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking ...
Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025 Enrollment completed ahead of schedule ...
In a recent study published in the Annals of Internal Medicine, researchers assess the efficacy of monoclonal antibodies (mAbs) in treating coronavirus disease 2019 (COVID-19) caused by different ...
Failing to maintain the MAB can lead to penalties, which could range from monthly maintenance fees to, in some cases, account closure. (Image: Freepik) The Monthly Average Balance (MAB) is the average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results